Jefferson Bridge Capital LLC Makes New $1.33 Million Investment in Pfizer Inc. $PFE

Jefferson Bridge Capital LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 53,410 shares of the biopharmaceutical company’s stock, valued at approximately $1,330,000. Pfizer makes up approximately 1.3% of Jefferson Bridge Capital LLC’s investment portfolio, making the stock its 28th biggest position.

A number of other large investors have also added to or reduced their stakes in PFE. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank raised its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its holdings in Pfizer by 79.1% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 4,941 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 2,182 shares in the last quarter. Finally, Transce3nd LLC raised its holdings in Pfizer by 59.4% in the second quarter. Transce3nd LLC now owns 1,879 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 700 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer filed a new Phase 1 study (PF-07328948), signaling continued pipeline investment and R&D momentum that supports longer-term growth prospects. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Positive Sentiment: Optimistic retail/analyst takes: at least one bullish piece argues PFE looks undervalued and could be a strong buy over a multi-year horizon, which can support investor appetite for the stock on dips. Prediction: In 5 Years, You’ll Wish You Bought Pfizer Stock Today
• Neutral Sentiment: Market correlation: some coverage notes today’s action is tied to broader S&P 500 moves rather than company-specific news, which can amplify price swings independent of fundamentals. Pfizer Inc. Market Action Tied To S&P 500 Index Movement
• Neutral Sentiment: Feature pieces weigh reasons to watch PFE while advising caution — helpful context for investors assessing valuation versus near-term risks. 2 Reasons to Watch PFE and 1 to Stay Cautious
• Neutral Sentiment: Sector competitive landscape: coverage of the expanding “diabesity” (GLP‑1) market highlights big opportunities for peers like Lilly and Novo Nordisk — an indirect signal that competition and missed participation in the category could pressure Pfizer’s long‑term growth narrative. The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, which prompted immediate selling pressure and raises short‑term uncertainty about their COVID franchise strategy. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Policy risk: reports that a Washington proposal could impose steep tariffs (or a 100% framework) on drugmakers without pricing agreements added regulatory and political risk that can pressure valuations in the near term. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Market reaction note: headline summaries show the stock has moved lower amid these combined factors, which explains today’s downward price action versus recent highs. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. BMO Capital Markets restated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Finally, Bank of America cut their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.19.

Pfizer Stock Performance

PFE opened at $27.10 on Wednesday. The firm’s 50-day moving average price is $27.14 and its 200-day moving average price is $25.89. The company has a market cap of $154.07 billion, a P/E ratio of 19.92 and a beta of 0.43. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.63 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.